



CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

(in millions)	2020				2021				2022	
	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30
Assets										
Cash, cash equivalents and marketable securities	\$ 24,314	\$ 21,190	\$ 26,049	\$ 7,910	\$ 6,245	\$ 7,361	\$ 6,837	\$ 7,829	\$ 6,752	\$ 7,000
Accounts receivable, net	3,907	3,194	3,913	4,892	3,925	4,149	4,566	4,493	3,787	4,118
Inventories	2,021	1,967	1,953	3,014	2,996	2,988	2,797	2,734	2,675	2,587
Property, plant and equipment, net	4,564	4,653	4,810	4,967	4,990	4,996	5,037	5,121	5,253	5,299
Intangible assets, net	13,502	13,225	12,939	33,126	34,781	34,341	33,900	33,455	30,331	29,885
Goodwill	4,117	4,117	4,117	8,108	8,334	8,334	8,332	8,332	8,314	8,314
Other assets	7,316	7,588	7,097	6,390	6,221	5,815	5,629	5,988	5,968	5,667
Total assets	<u>\$ 59,741</u>	<u>\$ 55,934</u>	<u>\$ 60,878</u>	<u>\$ 68,407</u>	<u>\$ 67,492</u>	<u>\$ 67,984</u>	<u>\$ 67,098</u>	<u>\$ 67,952</u>	<u>\$ 63,080</u>	<u>\$ 62,870</u>
Liabilities and Stockholders' Equity										
Current liabilities	\$ 8,879	\$ 10,564	\$ 9,509	\$ 11,397	\$ 9,705	\$ 10,214	\$ 10,245	\$ 11,610	\$ 8,558	\$ 9,220
Long-term liabilities	28,683	27,228	33,898	38,789	38,823	38,060	35,382	35,278	34,607	33,435
Stockholders' equity	22,179	18,142	17,471	18,221	18,964	19,710	21,471	21,064	19,915	20,215
Total liabilities and stockholders' equity	<u>\$ 59,741</u>	<u>\$ 55,934</u>	<u>\$ 60,878</u>	<u>\$ 68,407</u>	<u>\$ 67,492</u>	<u>\$ 67,984</u>	<u>\$ 67,098</u>	<u>\$ 67,952</u>	<u>\$ 63,080</u>	<u>\$ 62,870</u>



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)

(in millions, except percentages and per share amounts)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Revenues:												
Product sales	\$ 5,467	\$ 5,067	\$ 6,493	\$ 7,328	\$ 24,355	\$ 6,340	\$ 6,152	\$ 7,356	\$ 7,160	\$ 27,008	\$ 6,534	\$ 6,138
Royalty, contract and other revenues	81	76	84	93	334	83	65	65	84	297	56	122
Total revenues	5,548	5,143	6,577	7,421	24,689	6,423	6,217	7,421	7,244	27,305	6,590	6,260
Costs and expenses:												
Cost of goods sold	969	1,064	1,141	1,398	4,572	1,361	1,390	1,223	2,627	6,601	1,424	1,442
Research and development expenses	994	1,290	1,153	1,490	4,927	1,050	1,092	1,101	1,358	4,601	1,178	1,102
Acquired in-process research and development expenses	107	4,533	1,176	152	5,968	67	138	65	669	939	8	330
In-process research and development impairment	—	—	—	—	—	—	—	—	—	—	2,700	—
Selling, general and administrative expenses	1,076	1,239	1,106	1,730	5,151	1,055	1,351	1,190	1,650	5,246	1,083	1,357
Total costs and expenses	3,146	8,126	4,576	4,770	20,618	3,533	3,971	3,579	6,304	17,387	6,393	4,231
Income (loss) from operations	2,402	(2,983)	2,001	2,651	4,071	2,890	2,246	3,842	940	9,918	197	2,029
Interest expense	(241)	(240)	(236)	(267)	(984)	(257)	(256)	(250)	(238)	(1,001)	(238)	(242)
Other income (expense), net	(158)	250	(940)	(570)	(1,418)	(369)	(173)	(154)	57	(639)	(111)	(284)
Income (loss) before income taxes	2,003	(2,973)	825	1,814	1,669	2,264	1,817	3,438	759	8,278	(152)	1,503
Income tax (expense) benefit	(465)	(373)	(472)	(270)	(1,580)	(542)	(300)	(852)	(383)	(2,077)	164	(368)
Net income (loss)	1,538	(3,346)	353	1,544	89	1,722	1,517	2,586	376	6,201	12	1,135
Net loss attributable to noncontrolling interest	13	7	7	7	34	7	5	6	6	24	7	9
Net income (loss) attributable to Gilead	\$ 1,551	\$ (3,339)	\$ 360	\$ 1,551	\$ 123	\$ 1,729	\$ 1,522	\$ 2,592	\$ 382	\$ 6,225	\$ 19	\$ 1,144
Net income (loss) per share attributable to Gilead common stockholders - basic	\$ 1.23	\$ (2.66)	\$ 0.29	\$ 1.24	\$ 0.10	\$ 1.38	\$ 1.21	\$ 2.06	\$ 0.30	\$ 4.96	\$ 0.02	\$ 0.91
Shares used in per share calculation - basic	1,262	1,255	1,255	1,255	1,257	1,256	1,255	1,256	1,256	1,256	1,255	1,256
Net income (loss) per share attributable to Gilead common stockholders - diluted	\$ 1.22	\$ (2.66)	\$ 0.29	\$ 1.23	\$ 0.10	\$ 1.37	\$ 1.21	\$ 2.05	\$ 0.30	\$ 4.93	\$ 0.02	\$ 0.91
Shares used in per share calculation - diluted	1,270	1,255	1,261	1,259	1,263	1,262	1,260	1,262	1,262	1,262	1,262	1,260
Cash dividends declared per share	\$ 0.68	\$ 0.68	\$ 0.68	\$ 0.68	\$ 2.72	\$ 0.71	\$ 0.71	\$ 0.71	\$ 0.71	\$ 2.84	\$ 0.73	\$ 0.73
Product gross margin	82.3 %	79.0 %	82.4 %	80.9 %	81.2 %	78.5 %	77.4 %	83.4 %	63.3 %	75.6 %	78.2 %	76.5 %
Research and development expenses as a % of revenues	17.9 %	25.1 %	17.5 %	20.1 %	20.0 %	16.3 %	17.6 %	14.8 %	18.7 %	16.9 %	17.9 %	17.6 %
Selling, general and administrative expenses as a % of revenues	19.4 %	24.1 %	16.8 %	23.3 %	20.9 %	16.4 %	21.7 %	16.0 %	22.8 %	19.2 %	16.4 %	21.7 %
Operating margin	43.3 %	(58.0)%	30.4 %	35.7 %	16.5 %	45.0 %	36.1 %	51.8 %	13.0 %	36.3 %	3.0 %	32.4 %
Effective tax rate	23.2 %	(12.5)%	57.2 %	14.9 %	94.7 %	23.9 %	16.5 %	24.8 %	50.5 %	25.1 %	107.9 %	24.5 %

Certain amounts and percentages may not sum or recalculate due to rounding.

Please refer to disclosures regarding presentation of financial statements in our Press Release, issued by Gilead Sciences, Inc. on August 2, 2022 on Form 8-K, which is available on <http://investors.gilead.com>. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission ("SEC"), Gilead no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation..

Questions? Contact Investor_Relations@gilead.com



SELECTED CASH FLOW INFORMATION
(unaudited)

(in millions)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Net cash provided by operating activities	\$ 1,436	\$ 2,566	\$ 2,250	\$ 1,916	\$ 8,168	\$ 2,610	\$ 2,316	\$ 3,253	\$ 3,205	\$ 11,384	\$ 1,840	\$ 1,802
Net cash used in investing activities	(344)	(5,023)	(271)	(8,977)	(14,615)	(2,042)	(577)	(234)	(278)	(3,131)	(1,070)	(308)
Net cash provided by (used in) financing activities	(2,611)	(874)	4,124	131	770	(2,477)	(931)	(3,527)	(1,942)	(8,877)	(1,794)	(1,003)
Effect of exchange rate changes on cash and cash equivalents	(61)	26	37	41	43	(23)	20	(23)	(9)	(35)	(18)	(48)
Net change in cash and cash equivalents	(1,580)	(3,305)	6,140	(6,889)	(5,634)	(1,932)	828	(531)	976	(659)	(1,042)	443
Cash and cash equivalents, beginning of period	11,631	10,051	6,746	12,886	11,631	5,997	4,065	4,893	4,362	5,997	5,338	4,296
Cash and cash equivalents, end of period	\$ 10,051	\$ 6,746	\$ 12,886	\$ 5,997	\$ 5,997	\$ 4,065	\$ 4,893	\$ 4,362	\$ 5,338	\$ 5,338	\$ 4,296	\$ 4,739

(in millions)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Net cash provided by operating activities	\$ 1,436	\$ 2,566	\$ 2,250	\$ 1,916	\$ 8,168	\$ 2,610	\$ 2,316	\$ 3,253	\$ 3,205	\$ 11,384	\$ 1,840	\$ 1,802
Capital expenditures	(171)	(143)	(155)	(181)	(650)	(165)	(119)	(139)	(156)	(579)	(247)	(143)
Free cash flow ⁽¹⁾	\$ 1,265	\$ 2,423	\$ 2,095	\$ 1,735	\$ 7,518	\$ 2,445	\$ 2,197	\$ 3,114	\$ 3,049	\$ 10,805	\$ 1,593	\$ 1,659

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on August 2, 2022 on Form 8-K, which is available on <http://investors.gilead.com>.



NON-GAAP FINANCIAL INFORMATION⁽¹⁾
(unaudited)

(in millions, except percentages and per share amounts)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Non-GAAP:												
Cost of goods sold	\$ 703	\$ 798	\$ 875	\$ 918	\$ 3,294	\$ 855	\$ 836	\$ 736	\$ 2,111	\$ 4,538	\$ 825	\$ 886
Research and development expenses	\$ 994	\$ 1,177	\$ 1,150	\$ 1,424	\$ 4,745	\$ 1,044	\$ 1,042	\$ 1,063	\$ 1,315	\$ 4,464	\$ 1,150	\$ 1,102
Acquired in-process research and development expenses	\$ 107	\$ 4,533	\$ 1,176	\$ 152	\$ 5,968	\$ 67	\$ 138	\$ 65	\$ 669	\$ 939	\$ 8	\$ 330
Selling, general and administrative expenses	\$ 1,076	\$ 1,164	\$ 1,095	\$ 1,499	\$ 4,834	\$ 1,033	\$ 1,121	\$ 1,178	\$ 1,642	\$ 4,974	\$ 1,083	\$ 1,272
Other income (expense), net	\$ 125	\$ 49	\$ 29	\$ 46	\$ 249	\$ (18)	\$ 1	\$ (12)	\$ —	\$ (29)	\$ (15)	\$ 20
Diluted EPS	\$ 1.63	\$ (2.48)	\$ 1.29	\$ 2.15	\$ 2.59	\$ 2.04	\$ 1.81	\$ 2.65	\$ 0.69	\$ 7.18	\$ 2.12	\$ 1.58
Research and development expenses as a % of revenues	17.9 %	22.9 %	17.5 %	19.2 %	19.2 %	16.3 %	16.8 %	14.3 %	18.2 %	16.3 %	17.5 %	17.6 %
Product gross margin	87.1 %	84.3 %	86.5 %	87.5 %	86.5 %	86.5 %	86.4 %	90.0 %	70.5 %	83.2 %	87.4 %	85.6 %
Selling, general and administrative expenses as a % of revenues	19.4 %	22.6 %	16.6 %	20.2 %	19.6 %	16.1 %	18.0 %	15.9 %	22.7 %	18.2 %	16.4 %	20.3 %
Operating margin	48.1 %	(49.2)%	34.7 %	46.2 %	23.7 %	53.3 %	49.5 %	59.0 %	20.8 %	45.4 %	53.5 %	42.7 %
Effective tax rate	19.6 %	(14.7)%	22.1 %	15.7 %	36.4 %	18.4 %	19.5 %	18.9 %	32.2 %	20.4 %	18.4 %	19.3 %

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on August 2, 2022 on Form 8-K, which is available on <http://investors.gilead.com>. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 5 - 6. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission, the Company no longer excludes acquired IPR&D expenses from its non-GAAP financial measures. Acquired IPR&D expenses reflect the initial costs of externally-developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and other payments related to various collaborations and the initial costs of rights to IPR&D projects. Prior period non-GAAP financial measures are revised to conform to the new presentation.



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)

(in millions, except percentages and per share amounts)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Cost of goods sold reconciliation:												
GAAP cost of goods sold	\$ 969	\$ 1,064	\$ 1,141	\$ 1,398	\$ 4,572	\$ 1,361	\$ 1,390	\$ 1,223	\$ 2,627	\$ 6,601	\$ 1,424	\$ 1,442
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	(266)	(266)	(266)	(417)	(1,215)	(506)	(554)	(487)	(516)	(2,063)	(557)	(556)
Acquisition-related – other costs ⁽¹⁾	—	—	—	(63)	(63)	—	—	—	—	—	—	—
Other ⁽²⁾	—	—	—	—	—	—	—	—	—	—	(42)	—
Non-GAAP cost of goods sold	\$ 703	\$ 798	\$ 875	\$ 918	\$ 3,294	\$ 855	\$ 836	\$ 736	\$ 2,111	\$ 4,538	\$ 825	\$ 886
Product gross margin reconciliation:												
GAAP product gross margin	82.3 %	79.0 %	82.4 %	80.9 %	81.2 %	78.5 %	77.4 %	83.4 %	63.3 %	75.6 %	78.2 %	76.5 %
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	4.9 %	5.2 %	4.1 %	5.7 %	5.0 %	8.0 %	9.0 %	6.6 %	7.2 %	7.6 %	8.5 %	9.1 %
Acquisition-related – other costs ⁽¹⁾	— %	— %	— %	0.9 %	0.3 %	— %	— %	— %	— %	— %	— %	— %
Other ⁽²⁾	— %	— %	— %	— %	— %	— %	— %	— %	— %	— %	0.6 %	— %
Non-GAAP product gross margin	87.1 %	84.3 %	86.5 %	87.5 %	86.5 %	86.5 %	86.4 %	90.0 %	70.5 %	83.2 %	87.4 %	85.6 %
Research and development expenses reconciliation:												
GAAP research and development expenses	\$ 994	\$ 1,290	\$ 1,153	\$ 1,490	\$ 4,927	\$ 1,050	\$ 1,092	\$ 1,101	\$ 1,358	\$ 4,601	\$ 1,178	\$ 1,102
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	—	—	—	—	—	—	—	(67)	(42)	(109)	—	—
Acquisition-related – other costs ⁽¹⁾	—	(113)	(3)	(66)	(182)	(6)	(6)	(2)	—	(14)	(10)	—
Other ⁽²⁾	—	—	—	—	—	—	(44)	31	(1)	(14)	(18)	—
Non-GAAP research and development expenses	\$ 994	\$ 1,177	\$ 1,150	\$ 1,424	\$ 4,745	\$ 1,044	\$ 1,042	\$ 1,063	\$ 1,315	\$ 4,464	\$ 1,150	\$ 1,102
IPR&D impairment reconciliation:												
GAAP IPR&D impairment	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 2,700	\$ —
IPR&D impairment	—	—	—	—	—	—	—	—	—	—	(2,700)	—
Non-GAAP IPR&D impairment	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Selling, general and administrative expenses reconciliation:												
GAAP selling, general and administrative expenses	\$ 1,076	\$ 1,239	\$ 1,106	\$ 1,730	\$ 5,151	\$ 1,055	\$ 1,351	\$ 1,190	\$ 1,650	\$ 5,246	\$ 1,083	\$ 1,357
Acquisition-related – other costs ⁽¹⁾	—	(77)	(12)	(230)	(319)	(22)	(10)	(10)	(3)	(45)	—	—
Other ⁽²⁾	—	2	1	(1)	2	—	(220)	(2)	(5)	(227)	—	(85)
Non-GAAP selling, general and administrative expenses	\$ 1,076	\$ 1,164	\$ 1,095	\$ 1,499	\$ 4,834	\$ 1,033	\$ 1,121	\$ 1,178	\$ 1,642	\$ 4,974	\$ 1,083	\$ 1,272
Income (loss) from operations reconciliation:												
GAAP income (loss) from operations	\$ 2,402	\$ (2,983)	\$ 2,001	\$ 2,651	\$ 4,071	\$ 2,890	\$ 2,246	\$ 3,842	\$ 940	\$ 9,918	\$ 197	\$ 2,029
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	266	266	266	417	1,215	506	554	554	558	2,172	557	556
Acquisition-related – other costs ⁽¹⁾	—	190	15	359	564	28	16	12	3	59	10	—
IPR&D impairment	—	—	—	—	—	—	—	—	—	—	2,700	—
Other ⁽²⁾	—	(2)	(1)	1	(2)	—	264	(29)	6	241	60	85
Non-GAAP income (loss) from operations	\$ 2,668	\$ (2,529)	\$ 2,281	\$ 3,428	\$ 5,848	\$ 3,424	\$ 3,080	\$ 4,379	\$ 1,507	\$ 12,390	\$ 3,524	\$ 2,670
Operating margin reconciliation:												
GAAP operating margin	43.3 %	(58.0) %	30.4 %	35.7 %	16.5 %	45.0 %	36.1 %	51.8 %	13.0 %	36.3 %	3.0 %	32.4 %
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	4.8 %	5.2 %	4.0 %	5.6 %	4.9 %	7.9 %	8.9 %	7.5 %	7.7 %	8.0 %	8.5 %	8.9 %
Acquisition-related – other costs ⁽¹⁾	— %	3.7 %	0.2 %	4.8 %	2.3 %	0.4 %	0.3 %	0.2 %	0.1 %	0.2 %	0.2 %	— %
IPR&D impairment	— %	— %	— %	— %	— %	— %	— %	— %	— %	— %	41.0 %	— %
Other ⁽²⁾	— %	— %	— %	— %	— %	— %	4.2 %	(0.4) %	— %	0.9 %	0.9 %	1.4 %
Non-GAAP operating margin	48.1 %	(49.2) %	34.7 %	46.2 %	23.7 %	53.3 %	49.5 %	59.0 %	20.8 %	45.4 %	53.5 %	42.7 %
Other income (expense), net reconciliation:												
GAAP other income (expense), net	\$ (158)	\$ 250	\$ (940)	\$ (570)	\$ (1,418)	\$ (369)	\$ (173)	\$ (154)	\$ 57	\$ (639)	\$ (111)	\$ (284)
Loss (gain) from equity securities, net	283	(201)	969	616	1,667	351	174	142	(57)	610	96	303
Non-GAAP other income (expense), net	\$ 125	\$ 49	\$ 29	\$ 46	\$ 249	\$ (18)	\$ 1	\$ (12)	\$ —	\$ (29)	\$ (15)	\$ 20
Effective tax rate reconciliation:												
GAAP effective tax rate	23.2 %	(12.5) %	57.2 %	14.9 %	94.7 %	23.9 %	16.5 %	24.8 %	50.5 %	25.1 %	107.9 %	24.5 %
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments ⁽³⁾	(3.6) %	(2.2) %	(35.1) %	0.8 %	(58.3) %	(5.6) %	3.0 %	(5.9) %	(18.3) %	(4.7) %	(89.5) %	(5.2) %
Non-GAAP effective tax rate	19.6 %	(14.7) %	22.1 %	15.7 %	36.4 %	18.4 %	19.5 %	18.9 %	32.2 %	20.4 %	18.4 %	19.3 %

Questions? Contact Investor_Relations@gilead.com



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

(in millions, except per share amounts)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Net income (loss) attributable to Gilead reconciliation:												
GAAP net income (loss) attributable to Gilead	\$ 1,551	\$ (3,339)	\$ 360	\$ 1,551	\$ 123	\$ 1,729	\$ 1,522	\$ 2,592	\$ 382	\$ 6,225	\$ 19	\$ 1,144
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	224	224	225	329	1,002	409	446	446	449	1,750	443	442
Acquisition-related – other costs ⁽¹⁾	—	148	11	286	445	22	15	9	—	46	10	—
IPR&D impairment	—	—	—	—	—	—	—	—	—	—	2,057	—
Other ⁽²⁾	—	(2)	—	—	(2)	—	166	(23)	3	146	45	59
Loss (gain) from equity securities, net	256	(149)	983	628	1,718	364	169	154	(56)	631	64	308
Discrete and related tax charges ⁽³⁾	33	4	45	(82)	—	54	(40)	165	88	267	38	31
Non-GAAP net income (loss) attributable to Gilead	<u>\$ 2,064</u>	<u>\$ (3,114)</u>	<u>\$ 1,624</u>	<u>\$ 2,712</u>	<u>\$ 3,286</u>	<u>\$ 2,578</u>	<u>\$ 2,278</u>	<u>\$ 3,343</u>	<u>\$ 866</u>	<u>\$ 9,065</u>	<u>\$ 2,676</u>	<u>\$ 1,985</u>
Diluted earnings (loss) per share reconciliation:												
GAAP diluted earnings (loss) per share	\$ 1.22	\$ (2.66)	\$ 0.29	\$ 1.23	\$ 0.10	\$ 1.37	\$ 1.21	\$ 2.05	\$ 0.30	\$ 4.93	\$ 0.02	\$ 0.91
Acquisition-related – amortization of acquired intangibles and inventory step-up charges	0.18	0.18	0.18	0.26	0.79	0.32	0.35	0.35	0.36	1.39	0.35	0.35
Acquisition-related – other costs ⁽¹⁾	—	0.12	0.01	0.23	0.35	0.02	0.01	0.01	—	0.04	0.01	—
IPR&D impairment	—	—	—	—	—	—	—	—	—	—	1.63	—
Other ⁽²⁾	—	—	—	—	—	—	0.13	(0.01)	—	0.11	0.04	0.05
Loss (gain) from equity securities, net	0.20	(0.12)	0.78	0.50	1.36	0.29	0.13	0.12	(0.04)	0.50	0.05	0.24
Discrete and related tax charges ⁽³⁾	0.03	—	0.04	(0.07)	—	0.04	(0.03)	0.13	0.07	0.21	0.03	0.02
Non-GAAP diluted earnings (loss) per share	<u>\$ 1.63</u>	<u>\$ (2.48)</u>	<u>\$ 1.29</u>	<u>\$ 2.15</u>	<u>\$ 2.59</u>	<u>\$ 2.04</u>	<u>\$ 1.81</u>	<u>\$ 2.65</u>	<u>\$ 0.69</u>	<u>\$ 7.18</u>	<u>\$ 2.12</u>	<u>\$ 1.58</u>
Non-GAAP adjustment summary:												
Cost of goods sold adjustments	\$ 266	\$ 266	\$ 266	\$ 480	\$ 1,278	\$ 506	\$ 554	\$ 487	\$ 516	\$ 2,063	\$ 599	\$ 556
Research and development expenses adjustments	—	113	3	66	182	6	50	38	43	137	28	—
IPR&D impairment adjustments	—	—	—	—	—	—	—	—	—	—	2,700	—
Selling, general and administrative expenses adjustments	—	75	11	231	317	22	230	12	8	272	—	85
Total non-GAAP adjustments before other income (expense), net, and income taxes	266	454	280	777	1,777	534	834	537	567	2,472	3,327	641
Other income (expense), net, adjustments	283	(201)	969	616	1,667	351	174	142	(57)	610	96	303
Total non-GAAP adjustments before income taxes	549	253	1,249	1,393	3,444	885	1,008	679	510	3,082	3,423	945
Income tax effect of non-GAAP adjustments above	(69)	(32)	(30)	(150)	(281)	(90)	(212)	(93)	(114)	(509)	(803)	(135)
Discrete and related tax charges ⁽³⁾	33	4	45	(82)	—	54	(40)	165	88	267	38	31
Total non-GAAP adjustments after tax	<u>\$ 513</u>	<u>\$ 225</u>	<u>\$ 1,264</u>	<u>\$ 1,161</u>	<u>\$ 3,163</u>	<u>\$ 849</u>	<u>\$ 756</u>	<u>\$ 751</u>	<u>\$ 484</u>	<u>\$ 2,840</u>	<u>\$ 2,657</u>	<u>\$ 841</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Primarily includes employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's acquisitions of Immunomedics, Inc., Forty Seven, Inc. and MYR GmbH.

⁽²⁾ Primarily includes (i) various restructuring expenses and (ii) expenses related to donations of equity securities to the Gilead Foundation, a California nonprofit organization.

⁽³⁾ Includes discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.



**TOTAL REVENUE SUMMARY
(unaudited)**

(in millions)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
Product sales ⁽¹⁾ :												
HIV	\$ 4,134	\$ 4,000	\$ 4,547	\$ 4,257	\$ 16,938	\$ 3,650	\$ 3,938	\$ 4,189	\$ 4,538	\$ 16,315	\$ 3,707	\$ 4,228
HCV	729	448	464	423	2,064	510	549	429	393	1,881	399	448
HBV/HDV	186	219	211	244	860	220	237	247	265	969	235	234
Cell therapy	140	157	147	163	607	191	219	222	239	871	274	368
Trodelvy	—	—	—	49	49	72	89	101	118	380	146	159
Other	278	243	251	254	1,026	241	291	245	250	1,027	236	256
Total product sales excluding Veklury	5,467	5,067	5,620	5,390	21,544	4,884	5,323	5,433	5,803	21,443	4,998	5,693
Veklury	—	—	873	1,938	2,811	1,456	829	1,923	1,357	5,565	1,535	445
Total product sales	5,467	5,067	6,493	7,328	24,355	6,340	6,152	7,356	7,160	27,008	6,534	6,138
Royalty, contract and other revenues	81	76	84	93	334	83	65	65	84	297	56	122
Total revenues	\$ 5,548	\$ 5,143	\$ 6,577	\$ 7,421	\$ 24,689	\$ 6,423	\$ 6,217	\$ 7,421	\$ 7,244	\$ 27,305	\$ 6,590	\$ 6,260

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ See Product Sales Summary on pages 8-9 for more details.



PRODUCT SALES SUMMARY
(unaudited)

(in millions)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
HIV												
Biktarvy – U.S.	\$ 1,412	\$ 1,350	\$ 1,584	\$ 1,749	\$ 6,095	\$ 1,465	\$ 1,586	\$ 1,875	\$ 2,123	\$ 7,049	\$ 1,706	\$ 2,095
Biktarvy – Europe	181	153	194	207	735	216	237	254	262	969	261	268
Biktarvy – Other Intl	100	101	113	115	429	143	171	147	145	606	184	193
	<u>1,693</u>	<u>1,604</u>	<u>1,891</u>	<u>2,071</u>	<u>7,259</u>	<u>1,824</u>	<u>1,994</u>	<u>2,276</u>	<u>2,530</u>	<u>8,624</u>	<u>2,151</u>	<u>2,556</u>
Descovy – U.S.	363	337	424	402	1,526	282	357	355	403	1,397	311	397
Descovy – Europe	61	46	49	41	197	42	44	42	36	164	32	32
Descovy – Other Intl	34	34	35	35	138	35	34	36	34	139	31	32
	<u>458</u>	<u>417</u>	<u>508</u>	<u>478</u>	<u>1,861</u>	<u>359</u>	<u>435</u>	<u>433</u>	<u>473</u>	<u>1,700</u>	<u>374</u>	<u>460</u>
Genvoya – U.S.	612	646	669	678	2,605	506	551	576	634	2,267	457	482
Genvoya – Europe	151	109	116	114	490	106	100	100	85	391	77	72
Genvoya – Other Intl	61	61	61	60	243	61	55	68	37	221	48	29
	<u>824</u>	<u>816</u>	<u>846</u>	<u>852</u>	<u>3,338</u>	<u>673</u>	<u>706</u>	<u>744</u>	<u>756</u>	<u>2,879</u>	<u>582</u>	<u>582</u>
Odefsey – U.S.	269	273	309	321	1,172	240	258	275	303	1,076	232	255
Odefsey – Europe	127	98	116	109	450	113	111	112	104	440	96	97
Odefsey – Other Intl	13	11	12	14	50	14	13	12	13	52	11	12
	<u>409</u>	<u>382</u>	<u>437</u>	<u>444</u>	<u>1,672</u>	<u>367</u>	<u>382</u>	<u>399</u>	<u>420</u>	<u>1,568</u>	<u>339</u>	<u>364</u>
Revenue share – Symtuza ⁽¹⁾ – U.S.	72	90	82	87	331	89	86	86	94	355	86	80
Revenue share – Symtuza ⁽¹⁾ – Europe	38	40	34	37	149	44	40	41	40	165	44	42
Revenue share – Symtuza ⁽¹⁾ – Other Intl	2	2	2	2	8	2	3	3	3	11	3	4
	<u>112</u>	<u>132</u>	<u>118</u>	<u>126</u>	<u>488</u>	<u>135</u>	<u>129</u>	<u>130</u>	<u>137</u>	<u>531</u>	<u>132</u>	<u>126</u>
Complera/Eviplera – U.S.	24	27	26	12	89	25	20	28	29	102	17	20
Complera/Eviplera – Europe	47	42	35	35	159	34	39	31	38	142	24	31
Complera/Eviplera – Other Intl	5	3	9	4	21	4	3	5	2	14	4	3
	<u>76</u>	<u>72</u>	<u>70</u>	<u>51</u>	<u>269</u>	<u>63</u>	<u>62</u>	<u>64</u>	<u>69</u>	<u>258</u>	<u>44</u>	<u>54</u>
Stribild – U.S.	34	39	27	25	125	31	35	28	38	132	22	24
Stribild – Europe	17	12	13	12	54	11	11	11	10	43	8	8
Stribild – Other Intl	2	8	2	5	17	4	5	3	2	14	3	2
	<u>53</u>	<u>59</u>	<u>42</u>	<u>42</u>	<u>196</u>	<u>46</u>	<u>51</u>	<u>42</u>	<u>50</u>	<u>189</u>	<u>32</u>	<u>33</u>
Truvada – U.S.	383	370	492	131	1,376	119	94	55	46	314	28	24
Truvada – Europe	8	6	6	7	27	7	6	5	4	22	4	5
Truvada – Other Intl	15	11	11	8	45	9	8	7	11	35	6	5
	<u>406</u>	<u>387</u>	<u>509</u>	<u>146</u>	<u>1,448</u>	<u>135</u>	<u>108</u>	<u>67</u>	<u>61</u>	<u>371</u>	<u>38</u>	<u>34</u>
Other HIV ⁽²⁾ – U.S.	84	106	109	33	332	29	57	24	26	136	5	5
Other HIV ⁽²⁾ – Europe	9	6	6	5	26	5	8	6	11	30	4	9
Other HIV ⁽²⁾ – Other Intl	10	19	11	9	49	14	6	4	5	29	5	4
	<u>103</u>	<u>131</u>	<u>126</u>	<u>47</u>	<u>407</u>	<u>48</u>	<u>71</u>	<u>34</u>	<u>42</u>	<u>195</u>	<u>14</u>	<u>18</u>
Total HIV – U.S.	<u>3,253</u>	<u>3,238</u>	<u>3,722</u>	<u>3,438</u>	<u>13,651</u>	<u>2,786</u>	<u>3,044</u>	<u>3,302</u>	<u>3,696</u>	<u>12,828</u>	<u>2,862</u>	<u>3,383</u>
Total HIV – Europe	<u>639</u>	<u>512</u>	<u>569</u>	<u>567</u>	<u>2,287</u>	<u>578</u>	<u>596</u>	<u>602</u>	<u>590</u>	<u>2,366</u>	<u>550</u>	<u>562</u>
Total HIV – Other Intl	<u>242</u>	<u>250</u>	<u>256</u>	<u>252</u>	<u>1,000</u>	<u>286</u>	<u>298</u>	<u>285</u>	<u>252</u>	<u>1,121</u>	<u>295</u>	<u>282</u>
	<u>4,134</u>	<u>4,000</u>	<u>4,547</u>	<u>4,257</u>	<u>16,938</u>	<u>3,650</u>	<u>3,938</u>	<u>4,189</u>	<u>4,538</u>	<u>16,315</u>	<u>3,707</u>	<u>4,228</u>
HCV												
Ledipasvir/Sofosbuvir ⁽³⁾ – U.S.	53	24	36	(21)	92	19	30	14	21	84	13	6
Ledipasvir/Sofosbuvir ⁽³⁾ – Europe	11	4	11	3	29	16	3	5	7	31	4	4
Ledipasvir/Sofosbuvir ⁽³⁾ – Other Intl	48	39	37	27	151	21	29	26	21	97	18	13
	<u>112</u>	<u>67</u>	<u>84</u>	<u>9</u>	<u>272</u>	<u>56</u>	<u>62</u>	<u>45</u>	<u>49</u>	<u>212</u>	<u>35</u>	<u>23</u>
Sofosbuvir/Velpatasvir ⁽⁴⁾ – U.S.	311	165	170	218	864	214	262	173	166	815	162	227
Sofosbuvir/Velpatasvir ⁽⁴⁾ – Europe	122	57	74	84	337	75	82	77	82	316	83	75
Sofosbuvir/Velpatasvir ⁽⁴⁾ – Other Intl	131	113	86	68	398	92	98	82	59	331	85	74
	<u>564</u>	<u>335</u>	<u>330</u>	<u>370</u>	<u>1,599</u>	<u>381</u>	<u>442</u>	<u>332</u>	<u>307</u>	<u>1,462</u>	<u>330</u>	<u>376</u>
Other HCV ⁽⁵⁾ – U.S.	34	31	35	32	132	25	35	37	22	119	24	30
Other HCV ⁽⁵⁾ – Europe	15	9	13	11	48	44	8	12	10	74	8	16
Other HCV ⁽⁵⁾ – Other Intl	4	6	2	1	13	4	2	3	5	14	2	3
	<u>53</u>	<u>46</u>	<u>50</u>	<u>44</u>	<u>193</u>	<u>73</u>	<u>45</u>	<u>52</u>	<u>37</u>	<u>207</u>	<u>34</u>	<u>49</u>
Total HCV – U.S.	<u>398</u>	<u>220</u>	<u>241</u>	<u>229</u>	<u>1,088</u>	<u>258</u>	<u>327</u>	<u>224</u>	<u>209</u>	<u>1,018</u>	<u>199</u>	<u>263</u>
Total HCV – Europe	<u>148</u>	<u>70</u>	<u>98</u>	<u>98</u>	<u>414</u>	<u>135</u>	<u>93</u>	<u>94</u>	<u>99</u>	<u>421</u>	<u>95</u>	<u>94</u>
Total HCV – Other Intl	<u>183</u>	<u>158</u>	<u>125</u>	<u>96</u>	<u>562</u>	<u>117</u>	<u>129</u>	<u>111</u>	<u>85</u>	<u>442</u>	<u>105</u>	<u>91</u>
	<u>729</u>	<u>448</u>	<u>464</u>	<u>423</u>	<u>2,064</u>	<u>510</u>	<u>549</u>	<u>429</u>	<u>393</u>	<u>1,881</u>	<u>399</u>	<u>448</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

⁽²⁾ Includes Atripla, Emtriva and Tybost.

⁽³⁾ Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead's separate subsidiary, Asegua Therapeutics LLC.

⁽⁴⁾ Amounts consist of sales of Eplclusa and the authorized generic version of Eplclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC.

⁽⁵⁾ Includes Vosevi and Sovaldi.



PRODUCT SALES SUMMARY (continued)
(unaudited)

(in millions)	2020					2021					2022	
	Q1	Q2	Q3	Q4	FY20	Q1	Q2	Q3	Q4	FY21	Q1	Q2
HBV/HDV												
Vemlidy – U.S.	73	76	99	108	356	77	86	103	118	384	80	97
Vemlidy – Europe	7	7	8	7	29	8	8	9	9	34	9	9
Vemlidy – Other Intl	56	68	70	78	272	96	106	96	98	396	111	89
	<u>136</u>	<u>151</u>	<u>177</u>	<u>193</u>	<u>657</u>	<u>181</u>	<u>200</u>	<u>208</u>	<u>225</u>	<u>814</u>	<u>200</u>	<u>195</u>
Viread – U.S.	4	3	3	4	14	4	3	1	3	11	—	3
Viread – Europe	11	8	8	7	34	7	8	7	6	28	6	6
Viread – Other Intl	25	54	21	37	137	20	17	18	17	72	17	15
	<u>40</u>	<u>65</u>	<u>32</u>	<u>48</u>	<u>185</u>	<u>31</u>	<u>28</u>	<u>26</u>	<u>26</u>	<u>111</u>	<u>23</u>	<u>24</u>
Other HBV/HDV ⁽⁶⁾ – U.S.	8	1	—	1	10	—	—	—	1	2	—	—
Other HBV/HDV ⁽⁶⁾ – Europe	2	2	2	2	8	8	8	13	13	42	13	15
	<u>10</u>	<u>3</u>	<u>2</u>	<u>3</u>	<u>18</u>	<u>8</u>	<u>9</u>	<u>13</u>	<u>14</u>	<u>44</u>	<u>13</u>	<u>16</u>
Total HBV/HDV – U.S.	85	80	102	113	380	81	90	104	122	397	80	100
Total HBV/HDV – Europe	20	17	18	16	71	23	24	29	28	104	28	30
Total HBV/HDV – Other Intl	81	122	91	115	409	116	123	114	115	468	128	104
	<u>186</u>	<u>219</u>	<u>211</u>	<u>244</u>	<u>860</u>	<u>220</u>	<u>237</u>	<u>247</u>	<u>265</u>	<u>969</u>	<u>235</u>	<u>234</u>
Veklury												
Veklury – U.S.	—	—	785	1,241	2,026	820	416	1,527	877	3,640	801	41
Veklury – Europe	—	—	60	547	607	388	264	109	334	1,095	304	126
Veklury – Other Intl	—	—	28	150	178	248	149	287	146	830	430	278
	<u>—</u>	<u>—</u>	<u>873</u>	<u>1,938</u>	<u>2,811</u>	<u>1,456</u>	<u>829</u>	<u>1,923</u>	<u>1,357</u>	<u>5,565</u>	<u>1,535</u>	<u>445</u>
Cell therapy												
Tecartus – U.S.	—	—	5	29	34	27	32	35	42	136	47	53
Tecartus – Europe	—	1	4	5	10	4	9	12	15	40	15	20
Tecartus – Other International	—	—	—	—	—	—	—	—	—	—	1	—
	<u>—</u>	<u>1</u>	<u>9</u>	<u>34</u>	<u>44</u>	<u>31</u>	<u>41</u>	<u>47</u>	<u>57</u>	<u>176</u>	<u>63</u>	<u>73</u>
Yescarta – U.S.	103	95	85	79	362	92	108	100	106	406	125	193
Yescarta – Europe	37	56	51	47	191	61	61	66	65	253	77	85
Yescarta – Other Intl	—	5	2	3	10	7	9	9	11	36	9	17
	<u>140</u>	<u>156</u>	<u>138</u>	<u>129</u>	<u>563</u>	<u>160</u>	<u>178</u>	<u>175</u>	<u>182</u>	<u>695</u>	<u>211</u>	<u>295</u>
Total cell therapy – U.S.	103	95	90	108	396	119	140	135	148	542	172	246
Total cell therapy – Europe	37	57	55	52	201	65	70	78	80	293	92	105
Total cell therapy – Other Intl	—	5	2	3	10	7	9	9	11	36	10	17
	<u>140</u>	<u>157</u>	<u>147</u>	<u>163</u>	<u>607</u>	<u>191</u>	<u>219</u>	<u>222</u>	<u>239</u>	<u>871</u>	<u>274</u>	<u>368</u>
Trodelvy												
Trodelvy ⁽⁷⁾ – US	—	—	—	49	49	72	89	100	109	370	119	120
Trodelvy ⁽⁷⁾ – Europe	—	—	—	—	—	—	—	1	9	10	25	35
Trodelvy ⁽⁷⁾ – Other International	—	—	—	—	—	—	—	—	—	—	2	3
	<u>—</u>	<u>—</u>	<u>—</u>	<u>49</u>	<u>49</u>	<u>72</u>	<u>89</u>	<u>101</u>	<u>118</u>	<u>380</u>	<u>146</u>	<u>159</u>
Other												
AmBisome – U.S.	18	10	18	15	61	12	13	7	7	39	25	15
AmBisome – Europe	59	49	58	64	230	66	69	67	72	274	66	63
AmBisome – Other Intl	42	36	35	32	145	43	74	69	41	227	53	54
	<u>119</u>	<u>95</u>	<u>111</u>	<u>111</u>	<u>436</u>	<u>121</u>	<u>156</u>	<u>143</u>	<u>120</u>	<u>540</u>	<u>144</u>	<u>132</u>
Letairis – U.S.	83	80	78	73	314	54	57	46	49	206	43	49
Other ⁽⁸⁾ – U.S.	49	47	40	40	176	38	37	34	27	136	26	37
Other ⁽⁸⁾ – Europe	24	19	19	22	84	20	31	17	47	115	15	26
Other ⁽⁸⁾ – Other Intl	3	2	3	8	16	8	10	5	7	30	9	13
	<u>76</u>	<u>68</u>	<u>62</u>	<u>70</u>	<u>276</u>	<u>66</u>	<u>78</u>	<u>56</u>	<u>81</u>	<u>281</u>	<u>50</u>	<u>76</u>
Total other – U.S.	150	137	136	128	551	104	107	87	83	381	94	101
Total other – Europe	83	68	77	86	314	86	100	84	119	389	81	88
Total other – Other Intl	45	38	38	40	161	51	84	74	48	257	62	67
	<u>278</u>	<u>243</u>	<u>251</u>	<u>254</u>	<u>1,026</u>	<u>241</u>	<u>291</u>	<u>245</u>	<u>250</u>	<u>1,027</u>	<u>236</u>	<u>256</u>
Total product sales – U.S.	3,989	3,770	5,076	5,306	18,141	4,240	4,213	5,479	5,244	19,176	4,329	4,254
Total product sales – Europe	927	724	877	1,366	3,894	1,275	1,147	997	1,259	4,678	1,174	1,042
Total product sales – Other Intl	551	573	540	656	2,320	825	792	880	657	3,154	1,031	842
	<u>\$ 5,467</u>	<u>\$ 5,067</u>	<u>\$ 6,493</u>	<u>\$ 7,328</u>	<u>\$ 24,355</u>	<u>\$ 6,340</u>	<u>\$ 6,152</u>	<u>\$ 7,356</u>	<u>\$ 7,160</u>	<u>\$ 27,008</u>	<u>\$ 6,534</u>	<u>\$ 6,138</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽⁶⁾ Includes Hepcludex and Hepsera.

⁽⁷⁾ Trodelvy sales for the fourth quarter and full year 2020, including the period prior to the completion of Gilead's acquisition of Immunomedics, were \$64 million and \$137 million, respectively.

⁽⁸⁾ Includes Cayston, Jyseleca, Ranexa and Zydelig.